7 Best Peptides for Mitochondrial Health

What to Know Before Choosing a Peptide for Mitochondrial Health

Mitochondria are the organelles that produce most of the body's ATP, the energy currency that powers nearly every cellular process. When mitochondrial function declines, the downstream effects touch everything from physical endurance to cognitive clarity to how quickly cells respond to stress and repair themselves. That makes mitochondrial health one of the more compelling targets in the peptide space, and the range of compounds people are using for it reflects how many angles of attack exist: restoring the efficiency of existing mitochondria, triggering the creation of new ones, protecting cells from dying when mitochondria fail, or slowing the metabolic drag that builds with age.

Every peptide in this guide earned its place by the same standard: people are using it or actively discussing it for mitochondrial health. That includes FDA-approved compounds, compounds available through telemedicine as compounded preparations, and research-only peptides whose evidence base is still largely preclinical or community-reported. Approval status and evidence depth tell you how to describe a compound honestly, not whether it belongs on the list at all. Where the evidence is thin, this guide says so plainly.

The entries are numbered, but that numbering reflects how prominently each compound appears in published research and real-world use, not a verdict that one is better than another for you. A compound at number six may be exactly the right fit for a specific person's situation. The personalized part of that decision belongs in the app. What this guide does is give you an honest map of the field so you arrive at that decision knowing your options.

1. SS-31: The Only FDA-Approved Mitochondrial Peptide

SS-31, also known as elamipretide, is the most clinically advanced peptide in the mitochondrial health space and the only one to have received FDA approval. That approval came in September 2024, granted on an accelerated basis for Barth syndrome, a rare X-linked genetic disorder in which mitochondrial dysfunction causes severe fatigue, muscle weakness, and cardiac complications. The approval followed a pivotal clinical trial showing significant improvements in fatigue scores and a standardized measure of physical capacity called the six-minute walk test.

What makes SS-31 mechanistically distinctive is its specific molecular target. The inner membrane of every mitochondrion contains a phospholipid called cardiolipin, found almost nowhere else in the human body. Cardiolipin acts as the structural organizer for the electron transport chain, the series of protein complexes that generate ATP. When mitochondria age or come under oxidative stress, cardiolipin gets damaged, the electron transport chain loses its organized structure, and ATP output drops. SS-31 accumulates preferentially in the inner mitochondrial membrane at roughly five-thousand-fold concentration compared to other cellular compartments, and binds to cardiolipin to stabilize and protect it. The result is that the existing electron transport chain machinery works more efficiently, reactive oxygen species output drops, and ATP production is restored. Preclinical models showed this restoration happening within under an hour in aged tissue.

The clinical evidence behind SS-31 is more robust than for any other mitochondrial peptide. Across eighteen reviewed human trials covering mitochondrial myopathy, heart failure, macular degeneration, and Barth syndrome, both positive and negative outcomes have been published, which is a mark of a genuine evidence base rather than selective reporting. Outside the approved Barth syndrome indication, SS-31 is used off-label through licensed compounding pharmacies, commonly in longevity medicine practices for people with documented fatigue, declining exercise capacity, or age-related mitochondrial decline.

Community reporting on SS-31 is notably positive relative to most mitochondrial peptides, with some users in the chronic fatigue community describing substantial improvements in cognitive function and daily activity capacity. Side effects reported in both clinical and community contexts include temporary insomnia and constipation, both of which resolved when use was paused.

2. MOTS-c: The Exercise-Mimetic Signaling Molecule

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c, and it functions as a retrograde signaling molecule: it travels from the mitochondria to the cell nucleus, where it activates a genetic program that resets how the cell manages energy.

The central pathway involves AMPK, an enzyme sometimes described as the cell's master energy switch. When the ratio of AMP to ATP rises, which happens during exercise or caloric stress, AMPK activates and the cell shifts from storing energy to burning it. MOTS-c triggers this same switch. Downstream of AMPK, a transcription factor called PGC-1 alpha kicks off the creation of new mitochondria, a process called mitochondrial biogenesis. MOTS-c also enhances fatty acid oxidation, improves glucose uptake through a pathway that does not require insulin, and activates mitophagy, the cellular housekeeping process that identifies and removes damaged mitochondrial components. The functional picture is of a compound that mimics many of the metabolic effects of sustained aerobic exercise, which is why practitioners often describe it as an exercise mimetic.

Despite that compelling mechanism, the human evidence base for MOTS-c is limited as of mid-2026. No completed human clinical trials have been published for MOTS-c itself. A related analog called CB4211 entered early Phase 1 human study phases, but no results from those studies have been published. The available evidence comes from animal models, where MOTS-c improved sprint capacity in aging mice and regulated insulin sensitivity and glucose metabolism, and from preclinical biochemistry establishing the AMPK and PGC-1 alpha pathway.

Community sentiment around MOTS-c is more mixed than the theoretical promise suggests. Reports from users who ran MOTS-c protocols for several months without noticeable effect are not uncommon. Longevity clinics cite it frequently, but real-world user data has not consistently matched the mechanistic excitement. Safety considerations deserve attention given the absence of rigorous human trial data: community-reported side effects include injection site irritation, heart palpitations, insomnia, headache, and nausea. Contradictory preclinical studies have also raised questions about whether MOTS-c's AMPK-activating mechanism might promote tumor growth in people with active cancer, and those with current cancer diagnoses are generally advised to avoid it. People taking metformin or similar AMPK-activating medications should be aware of potential additive effects.

3. Humanin: A Cellular Survival Signal

Humanin is an endogenous mitochondrial-derived peptide, produced naturally in the body and declining with age. Its biological role is cytoprotective: it is a cellular survival signal that prevents cells from dying when they come under metabolic or oxidative stress.

The mechanism is specific. Inside a cell under stress, a protein called BAX can translocate to the mitochondrial membrane and trigger apoptosis, the cell's self-destruction program. Humanin binds directly to BAX and blocks that translocation. It also interacts with a receptor complex involving proteins called gp130, WSX1, and the CNTF receptor, activating survival signaling cascades through pathways known as AKT and STAT3. Separately, Humanin suppresses an enzyme called NOX2 that generates reactive oxygen species, reducing the oxidative load on the cell. The net effect is a peptide that keeps cells alive and functioning under conditions that would otherwise kill them, which is relevant to age-related decline in tissues throughout the body, including the brain and the heart.

No completed clinical trials studying Humanin supplementation for mitochondrial health or any related indication have been published as of 2026. What exists in the published literature is largely observational: lower circulating Humanin levels correlate with metabolic disease, cardiovascular risk, and cognitive decline in population studies. That correlation establishes biological relevance without establishing whether supplementing it changes outcomes. Research into whether Humanin's cytoprotective properties might reduce the side effects of chemotherapy is ongoing but has not yet produced published therapeutic results.

Humanin is available as a research compound. People use it in anti-aging protocols for general cellular protection, particularly framing it around brain health and cardiovascular resilience. The evidence here is experiential rather than clinical, and the honest framing for anyone considering it is that the biological rationale is solid and the human therapeutic evidence has not yet caught up with it.

4. 5-Amino-1MQ: The NNMT Inhibitor

5-Amino-1MQ takes a different angle than the other compounds on this list. Rather than directly targeting a mitochondrial structure or activating a biogenesis pathway, it works by blocking an enzyme called NNMT, nicotinamide N-methyltransferase. That enzyme, when overactive, consumes nicotinamide in a way that diverts it away from the NAD biosynthesis pathway and effectively creates a metabolic bottleneck. By inhibiting NNMT, 5-Amino-1MQ keeps nicotinamide available for NAD production, which supports mitochondrial energy metabolism downstream.

The practical framing in longevity circles is metabolic efficiency. It is used by people who want to counter the metabolic drag that accumulates with age or with excess adiposity, where NNMT activity tends to be elevated. The mechanism data supporting its role as a potent NNMT inhibitor comes from biochemical and cell-based research rather than from completed human clinical trials: as of 2026, no completed human trials have been published for this compound. It is a newer entrant to the mitochondrial health conversation, and much of what informs its use comes from mechanistic data and emerging practitioner experience.

Whether 5-Amino-1MQ is technically a peptide depends on how strictly you define the category. It is sometimes classified as a small molecule rather than a traditional amino acid chain. It appears consistently in the same clinical and community discussions as the peptides here, which is why it earns a place on this list. Access is through research-only channels or compounded preparations from licensed providers, and the safety profile is not yet established through rigorous clinical study.

5. Epitalon: Telomere Support With Downstream Mitochondrial Effects

Epitalon is a tetrapeptide made of four amino acids, and its best-supported biological role involves telomeres, the protective caps at the ends of chromosomes that shorten with each cell division. By activating an enzyme called telomerase, Epitalon slows that shortening, which is associated with the broader biology of cellular aging. Its mitochondrial relevance is downstream of this primary mechanism: cells aging more slowly and under less oxidative stress tend to maintain better mitochondrial function, and Epitalon also appears to restore the antioxidant capacity of mitochondria that has been diminished by aging, partly through its influence on the pineal-melatonin axis.

The mitochondrial mechanism here is less direct than SS-31's cardiolipin stabilization or MOTS-c's AMPK activation. Epitalon does not target a mitochondrial structure directly. Its place in mitochondrial health protocols reflects a systems-level view: slowing the cellular aging process and restoring antioxidant defenses allows mitochondrial function to improve as a downstream consequence. That framing is reasonable given the biology, but it means the evidence for direct mitochondrial benefit is thinner than the evidence for Epitalon's telomere-related effects.

Epitalon has been studied more in Russian and Eastern European research traditions than in Western clinical trial infrastructure, and some peer-reviewed evidence for its telomere biology exists. For mitochondrial health specifically, no dedicated clinical trial data has been published. People who include Epitalon in mitochondrial protocols typically do so as part of a broader anti-aging stack, treating it as a cellular aging intervention with secondary mitochondrial benefits rather than a primary mitochondrial compound.

6. GHK-Cu: Antioxidant Defense and Electron Transport Support

GHK-Cu is a naturally occurring copper-binding tripeptide that has been studied more extensively than most compounds in the mitochondrial health conversation, though the research has primarily addressed its systemic anti-aging effects rather than mitochondrial function specifically. Its connection to mitochondrial health runs through two mechanisms.

The first is NRF2 activation. NRF2 is a transcription factor that acts as the master regulator of the cellular antioxidant defense system. When activated, it triggers the production of a broad suite of antioxidant enzymes that reduce oxidative damage throughout the cell, including inside mitochondria. Because oxidative stress is one of the primary drivers of mitochondrial dysfunction, robust NRF2 activation has real relevance to mitochondrial health.

The second mechanism is more specific. Complex IV, also called cytochrome c oxidase, is the final protein complex in the electron transport chain, the step where electrons are handed off to oxygen and ATP synthesis is completed. Complex IV requires copper as a cofactor to function, and GHK-Cu, by delivering copper in a bioavailable form, supports Complex IV activity directly.

GHK-Cu has a broader and more independently replicated body of evidence for systemic anti-aging effects than most peptides in any category. That evidence is strongest for topical applications and for gene expression studies showing that GHK-Cu influences hundreds of genes involved in tissue repair and inflammation. No clinical trials studying GHK-Cu specifically for mitochondrial outcomes have been published, so the mitochondrial framing draws on the mechanism and on systemic evidence rather than dedicated mitochondrial research. It appears regularly in longevity and anti-aging protocols and is widely available in both topical and research-grade injectable forms.

7. SHLP2 and SHLP3: The Emerging Humanin Relatives

SHLP2 and SHLP3, or Small Humanin-Like Peptides 2 and 3, belong to the same family of mitochondrial-derived peptides as Humanin. They are encoded in the same mitochondrial ribosomal RNA region and share Humanin's general cytoprotective profile, with some distinctions in how they act.

SHLP2 functions as a protein chaperone, helping other proteins fold correctly under cellular stress conditions. Both SHLP2 and SHLP3 appear to reduce reactive oxygen species production, enhance mitochondrial function, and promote mitochondrial biogenesis in preclinical models. Investigations into their relevance for metabolic health and insulin sensitivity are ongoing.

No human clinical trial data has been published for either compound as of 2026. The evidence is early stage, grounded in cell and animal research and in observational biomarker studies showing that lower circulating levels correlate with metabolic and age-related disease. That correlation is biologically interesting and establishes the rationale for investigating them as therapeutics, but it does not establish that supplementing them changes outcomes in humans. Both are available only as research compounds. They appear on this list because they are part of an active and growing conversation about mitochondrial-derived peptides, showing up alongside MOTS-c and Humanin in longevity research discussions and community protocols, even though the clinical chapter of their story is still being written.

How These Peptides Compare

Frequently Asked Questions

What is the difference between mitochondrial biogenesis and mitochondrial efficiency?

Mitochondrial biogenesis is the process of creating new mitochondria inside a cell, increasing the total number of these energy-producing organelles. Mitochondrial efficiency refers to how well existing mitochondria are functioning, specifically how much ATP they produce relative to energy inputs and how much damaging oxidative waste they generate as a byproduct. Some peptides, like MOTS-c, primarily promote biogenesis, while others, like SS-31, focus on restoring the efficiency of mitochondria that are already present. These are complementary rather than competing goals, which is why some protocols combine compounds from both categories.

Are any of these peptides legal to use in the United States?

SS-31 (elamipretide) is FDA-approved for Barth syndrome and can be prescribed legally for that indication; off-label use through licensed compounding pharmacies with a physician's prescription is also legal. The remaining compounds on this list are not FDA-approved for any indication as of 2026 and are classified as investigational or research compounds. Access pathways vary: some are available through telemedicine-based compounding programs, others only through research-only distributors. Regulatory status can change and varies by country, so verifying the current legal status in your jurisdiction before pursuing any of these compounds is important.

Does exercise accomplish the same thing as these peptides?

Exercise, particularly sustained aerobic work and high-intensity interval training, is one of the most potent natural stimulators of mitochondrial biogenesis and AMPK activation. MOTS-c is sometimes described as an exercise mimetic precisely because it activates some of the same pathways that physical training does. Many practitioners and community users treat exercise as foundational and view mitochondrial peptides as adjunctive tools rather than replacements. The peptides here address specific molecular mechanisms, but the biology of mitochondrial health responds strongly to movement, and the research and biohacking communities largely agree that lifestyle factors come first.

Which of these peptides has the most complete safety data?

SS-31 (elamipretide) has the most complete safety profile of any compound on this list by a wide margin, because it has been evaluated in multiple human clinical trials and went through the FDA approval process. For the other compounds, safety data in humans is limited or absent entirely. MOTS-c, Humanin, the SHLPs, 5-Amino-1MQ, and Epitalon all lack the rigorous clinical trial safety programs that would establish their human risk profiles comprehensively. GHK-Cu has a longer history of human topical use with a generally favorable profile, though injectable systemic use has less documentation behind it. Anyone considering these compounds should discuss the incomplete safety picture with a qualified healthcare provider before proceeding.

Can SS-31 and MOTS-c be used together?

Combining SS-31 and MOTS-c is one of the more commonly discussed approaches in longevity medicine, with the logic that SS-31 optimizes the function of existing mitochondria while MOTS-c drives the creation of new ones, addressing mitochondrial aging from two complementary angles at once. No controlled research has studied this combination in humans, so what is known comes from clinical observation and user-reported experience rather than trial data. Decisions about combining compounds of this kind involve real unknowns and should be made with physician guidance.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and user-reported real-world use of peptides for mitochondrial health in one place.